Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms

Table 2

Statistically significant genes related to JAK-STAT pathway in CD34⁺ cells of MPNs according to JAK2V617F mutant allele burden.

	Control	ET		PV		PMF
JAK2	−	−	+	Hetero	Homo	−	+
Genes	AV ± SD	AV ± SD	AV ± SD	AV ± SD	AV ± SD	AV ± SD	AV ± SD
AKT2	0.94 ± 0.18	1.11 ± 0.58	0.80 ± 0.40	0.66 ± 0.37	1.3 ± 0.1	0.7 ± 0.30	1.1 ± 0.17
CSF3R	2.83 ± 0.20	2.99 ± 0.37	3.8 ± 0.6	3.2 ± 0.6	3.2 ± 0.2	2.92 ± 1.01	3.20 ± 0.50
CBL	0.49 ± 0.45	−0.1 ± 0.3	0.28 ± 0.65	0.29 ± 0.06	0.61 ± 0.14	0.16 ± 0.85	0.79 ± 0.13
CCND2	0.30 ± 0.55	0.01 ± 0.05	−0.38 ± 0.6	0.56 ± 0.39	0.38 ± 0.38	0.02 ± 0.20	0.33 ± 0.86
CCND3	0.21 ± 0.22	1.1 ± 0.5	0.9 ± 0.4	0.66 ± 0.57	0.9 ± 0.3	1.2 ± 0.4	0.76 ± 0.2
CNTFR	0.52 ± 0.99	0.65 ± 0.83	0.97 ± 0.71	0.25 ± 0.47	−1.03 ± 0.2	−1.2	−0.64 ± 1.3
CREBBP	0.23 ± 0.60	−0.35 ± 0.3	0.35 ± 0.34	0.45 ± 0.44	0.10 ± 0.51	−0.41 ± 0.6	0.05 ± 0.58
GRB2	1.65		2.05		1.91 ± 0.12	1.48
IFNAR2	0.51 ± 1.13	1.41 ± 0.46	1.76 ± 0.49	1.38 ± 0.25	1.32 ± 0.38	1.23 ± 0.69	0.83
IFNGR1	0.77 ± 0.22	0.92	1.14 ± 0.28	0.85 ± 0.12	1.18 ± 0.40	1.88
IFNGR2	0.77 ± 0.13	2.06	1.58 ± 0.60	1.94 ± 0.48	2.0 ± 0.1	1.96	1.87
IL10RB	0.96 ± 0.28	0.88 ± 0.55	1.52 ± 0.60	1.23 ± 0.49	0.99 ± 0.79	0.86 ± 1.01	0.80 ± 0.05
IL11RA	1.69 ± 0.13	0.31	1.87	1.66 ± 0.15	1.92 ± 0.39	1.49
IL15			1.1	2.14	2.24 ± 0.04
IL15RA	0.76 ± 0.47	0.19 ± 0.09	0.50 ± 0.34	0.27 ± 0.19	0.41 ± 0.07	0.16 ± 0.32	0.60 ± 0.39
IL23A	−1.18 ± 0.2	−0.7 ± 0.4	−1.11 ± 0.4	−0.75 ± 0.4	−0.5 ± 0.4	−1.3 ± 0.2	−1.7 ± 0.02
IL6ST	−1.10 ± 0.2	−0.46 ± 0.4	0.1 ± 0.6	0.06 ± 0.4	−0.1 ± 0.6	−0.92 ± 0.7	−0.84
JAK1	0.88 ± 0.24	1.2	0.93	1.42 ± 0.03	1.7 ± 0.1	1.47	1.11
JAK2	2.25		3.54 ± 0.81	4.07 ± 0.27	3.96 ± 0.57		3.01
LEPR	0.18	0.92	0.77	0.81	0.39 ± 0.21	1.13	1.07
MYC	−1.86 ± 0.3	−2.28 ± 0.2	−1.70 ± 0.4	−1.27 ± 0.7	−1.58 ± 0.5	−1.70 ± 1.1	−0.79
PIAS1	0.48 ± 0.38	0.04 ± 0.49	1.10 ± 0.61	1.04 ± 0.37	0.97 ± 0.12	0.21 ± 0.69	0.61 ± 0.05
PIAS4	1.88 ± 0.43	2.05 ± 0.20	2.24 ± 0.77	1.86 ± 0.42	1.84 ± 0.12	1.89 ± 0.12	2.06 ± 0.51
PIK3CA			1.45	1.51	1.64 ± 0.13
PIK3R1	0.72	1.04	2.41	2.45 ± 0.68	1.95	2.21
PIM1	0.28 ± 0.2	0.90 ± 0.19	1.10 ± 0.48	1.37 ± 0.4	1.42 ± 0.4	1.03 ± 0.38	0.82 ± 0.28
PTPN11	0.78 ± 0.53	1.10 ± 0.46	0.84 ± 0.38	1.09 ± 0.43	1.03 ± 0.4	0.91	0.44 ± 0.16
PTPN6	0.44 ± 0.43	0.70 ± 0.18	1.35 ± 0.4	1.12 ± 0.60	0.41 ± 0.19	0.05 ± 0.23	0.47
SOCS2	1.48 ± 0.61	1.12 ± 0.94	1.21 ± 0.87	1.71 ± 0.73	1.75 ± 1.09	2.06 ± 0.04	2.20 ± 0.90
SPRED2	0.17 ± 0.34	−0.45 ± 0.2	−0.58			−0.82	−0.73
SPRY4	−0.13 ± 0.7	−0.14 ± 0.7	−0.35 ± 0.2	−0.61 ± 0.2	−1.14 ± 0.2	−1.03	−1.00 ± 0.7
STAT1	3.60 ± 0.55	3.37 ± 0.80	4.68 ± 0.8	4.4 ± 0.05	5.1 ± 0.5	3.31 ± 1.44	4.18 ± 0.39
STAT2	1.45 ± 0.51	1.57 ± 0.38	2.39 ± 0.6	2.25 ± 0.2	2.01 ± 0.42	1.58 ± 0.74	1.75 ± 0.35
STAT3	1.13 ± 0.26	1.54 ± 0.07	1.32 ± 0.30	1.05 ± 0.81	1.8 ± 0.3	1.59 ± 0.13	1.62 ± 0.57
STAT5A	1.39 ± 0.25	0.8 ± 0.01	0.90 ± 0.53	0.99 ± 0.43	1.01 ± 0.2	0.5 ± 0.2	1.93
TYK2	0.36 ± 0.28	0.63	0.85 ± 0.43	0.75 ± 0.33	0.35 ± 0.32	0.58

, , and gene expression in MPNs versus control.